Ionis Pharmaceuticals (LTS:0JDI) Current Deferred Revenue: $73.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JDI Ionis Pharmaceuticals Inc LTS:0JDI
66 GF Score
Price $51.73
GF Value $47.76
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Current Deferred Revenue?

Ionis Pharmaceuticals LTS:0JDI -2.84% 66 Current Deferred Revenue is $73.8 Mil as of Jun. 2026. GuruFocus rates LTS:0JDI with a GF Score™ of 66/100 and a GF Value™ of $47.76 (Fairly Valued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Ionis Pharmaceuticals's current deferred revenue for the quarter that ended in Jun. 2026 was $73.8 Mil.

Ionis Pharmaceuticals Current Deferred Revenue Related Terms

Ionis Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Current Deferred Revenue Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 97.71 90.58 151.13 78.99 73.76

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.91 76.99 73.76 69.20 73.84
LTS:0JDI
66GF Score
Ionis Pharmaceuticals Inc LTS:0JDI
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $73.8 Mil mean?
Ionis Pharmaceuticals (LTS:0JDI) has a Current Deferred Revenue of $73.8 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Current Deferred Revenue too high?
Ionis Pharmaceuticals' current Current Deferred Revenue is $73.8 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Current Deferred Revenue compare to KYMR and PRAX?
Ionis Pharmaceuticals' Current Deferred Revenue of $73.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Current Deferred Revenue is $73.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Fairly Valued. The stock's GF Value™ is $47.76, compared to a current price of $51.73 — trading 8.3% above its estimated fair value. The current Current Deferred Revenue is $73.8 Mil. Ionis Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Current Deferred Revenue is $73.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $51.73 is trading 8.3% above its estimated GF Value™ of $47.76. GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0JDI:

  • Current Deferred Revenue: $73.8 Mil
  • GF Value™: $47.76 vs. price of $51.73 (8.3% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
66GF Score

Get the complete analysis for LTS:0JDI

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.73
Price
$47.76
GF Value